UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No. 1)
Filed by the Registrant ( )
Filed by a Party other than the Registrant (X)
Check the appropriate box:
( ) Preliminary Proxy Statement ( ) Confidential for Use of the
Commission Only (as
(x) Definitive Proxy Statement permitted by Rule 14a-6(e)(2))
( ) Definitive Additional Materials
( ) Soliciting Material Pursuant to (Section)240.14a-11(c) or
(Section)240.14a-12
_________________Novametrix Medical Systems, Inc.____________________________
(Name of Registrant as Specified In Its Charter)
________Paul A. Cote, on behalf of Novametrix 13D Shareholders Group___________
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
( ) $125 per Exchange Act Rules 0-11(c)(1)(ii), 14a-6(i)(1), 14a-6(i)(2)
or item 22(a)(2) of Schedule 14A.
( ) $500 per each party to the contoversy pursuant to Exchange Act
Rule 14a-6(i)(3). (Fee of $500 previously paid.)
( ) Fee computed on table below per Exchange Act Rules 14a-6(i)(4)
and 0-11.
1) Title of each class of securities to which transaction applies:
_____________________________________________________________________________
2) Aggregate number of securities to which transaction applies:
_____________________________________________________________________________
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
_____________________________________________________________________________
4) Proposed maximum aggregate value of transaction:
_____________________________________________________________________________
5) Total fee paid:
_____________________________________________________________________________
DEFINITIVE PROXY STATEMENT
13D SHAREHOLDERS GROUP
John C. Allen, Sr. Donn Gifford
Lillian I. Allen Linda Gifford
Roland R. Batson Ginette Gladu
Richard Boulet Robert R. Gladu
Joan P. Cote Andrew Gross
Paul A. Cote Dana Gross
Normand F. Doyon John F. Gross
Pauline G. Doyon Susan T. Gross
Sandra Dunham Diane James
Thomas B. Dunham Richard James
Adrienne R. Emmi William Lagerson
Anthony N. Emmi Pierre Levesque
Armen Ghugasian Edgar Morin
Takuhe Ghugasian John Orestis
Vartan Ghugasian Raymond E. Robichaud
DEFINITIVE PROXY STATEMENT
13D Shareholders Group
Regarding
NOVAMETRIX MEDICAL SYSTEMS, INC.
The enclosed proxy is solicited by the 13D Shareholders Group (names
listed above) of Novametrix Medical Systems, Inc. ("Novametrix") for use in
voting at the annual meeting regarding the matters described in this proxy
statement and in the accompanying materials. Each of the members of the Group
is a shareholder of Novametrix and each has no connection to existing
management. The solicitation is being done to elect two shareholder
representatives to the Board of Directors of Novametrix and to oppose the
proposal of the existing Board of Directors to merge Novametrix with Andros
Holdings, Inc. ("Andros").
Original Proxy Cards
You may have previously received proxy cards from the 13D Group with
respect to a Shareholder Proposal and the election of directors.
THESE CARDS ARE NOT VALID AND SHOULD NOT BE USED. THE PROXY CARD ENCLOSED
HEREWITH IS THE ONLY VALID CARD TO BE USED IN VOTING AT THE ANNUAL MEETING.
Date, Time and Place of Annual Meeting
(a) Date of annual meeting of shareholders of Novametrix Medical Systems,
Inc. is November 25, 1996 at 2:00 p.m.
Place of annual meeting: The Drake Swissotel, 440 Park Avenue, New
York, New York
Mailing address of executive officers:
Novametrix Medical Systems, Inc.
56 Carpenter Lane
Wallingford, Connecticut 06492
(b) The definitive proxy statement will be first given to security holders
on or after November 1, 1996, if the Securities and Exchange
Commission reduces the ten (10) day waiting period.
THE DEFINITIVE PROXY STATEMENT TO BE GIVEN TO STOCKHOLDERS ON OR AFTER
NOVEMBER 1, 1996, IF THE SECURITIES AND EXCHANGE COMMISSION REDUCES THE
TEN (10) DAY WAITING PERIOD
<PAGE>
Voting and Revocability of Proxy
When proxies are properly dated, executed and returned, the shares they
represent will be voted at the annual meeting in accordance with your
instructions as stockholders. If no specific instructions are given, the
shares will be voted FOR the election of the nominees for directors set
forth herein and FOR ratification of the proposal set forth herein. Any
proxy given by any stockholder may be revoked by the stockholder prior to
its exercise by voting in person at the annual meeting, by giving written
notice to the Secretary of Novametrix prior to the annual meeting or by
giving a later dated proxy.
Persons Making the Solicitation and Interest of Certain Persons in Matters to
be Acted Upon
(a) Solicitation is made by 13D Shareholders Group consisting of the
persons identified and described in Attachment A. Solicitation will
be made by personal meetings or telephone conversations, by members of
the 13D Shareholders Group, and mailings that will include the proxy
statement, proxy and letters.
(b) No employees of Novametrix or any member of the 13D Shareholders Group
will be used to solicit security holders.
(c) No specially engaged employees, representatives or other persons will
be used to solicit proxies.
(d) Estimated expenses of the 13D Shareholders Group of this solicitation
are $35,000; approximately $25,000 of expenses have been incurred to
date.
(e) The cost of the solicitation has been borne initially by the members
of the 13D Shareholders Group described in Attachment A.
Reimbursement will be sought from the registrant, Novametrix, if the
solicitation is successful.
Voting Securities And Principal Holders Thereof
(a) Number of common shares entitled to vote: As of June 28, 1996, based
upon publicly available statements of the Company, there were
approximately 6,647,512 shares of common stock of Novametrix, 40,000
shares of Class B preferred stock of Novametrix, and warrants to
purchase up to 2,547,514 shares of Novametrix common stock. Each
holder of common stock as of the record date of September 27, 1996 is
entitled to one vote per share of stock owned. Each share of
preferred stock is entitled to eleven votes at the annual meeting.
Holders of warrants who have not exercised their warrants on or prior
to September 27, 1996 by the purchase of shares of common stock are
not entitled to vote such warrants.
(b) The record date is September 27, 1996.
(c) There are no cumulative voting rights.
(d) (i) Security Ownership of Certain Beneficial Owners
The stockholders (including any "group," as that term is used in
Section 13(d)(3) of the Securities Exchange Act of 1934) who, to
the knowledge of the 13D Shareholders Group, owned beneficially
more than five percent of any class of the outstanding voting
securities of the Company as of September 30, 1996, and their
respective shareholdings as of such date (according to information
furnished by them to the Company), are set forth in the following
table. Except as indicated in the footnotes to the table, all of
such shares are owned with sole voting and investment power.<F1>
<F1> For all information other than the Schedule 13D Shareholders Group, the
information is as of September 30, 1996 and derived solely from the proxy
statement of the Company dated October 23, 1996.
Title of Shares Percent
Name and Address Class Beneficially Owned of Class
First Union Corporation Common 716,182 (1)(2) 9.1%
One First Union Center Series B
Charlotte, NC 28288 Preferred 40,000 (2) 100.0%
William J. Lacourciere Common 417,490 (3) 5.2%
One Barnes Industrial Park Rd
Wallingford, Connecticut 06492
13D Shareholders Group Common 864,810 (4) 10.8%
(1) Consists of (i) 444,444 shares issuable upon the conversion of 40,000
shares of Series B Preferred Stock and (ii) 271,738 shares issuable
upon the exercise of currently exercisable warrants formerly held by
First Fidelity Incorporated ("First Fidelity"), a wholly owned
subsidiary of First Fidelity Bancorporation, which warrants will expire
on May 23, 2000. The Series B Preferred Stock and warrants presently
held by First Union Corporation ("First Union") as the result of First
Union's merger with First Fidelity consummated in January, 1996, were
formerly held by First Fidelity Bank, Connecticut ("FFB-CT"), formerly
known as Union Trust Company prior to its acquisition by First Fidelity
Bancorporation.
(2) Information as to the holdings of First Union is based upon a report on
Schedule 13D filed with the Commission by FFB-CT and Northeast Bancorp,
Inc., its parent corporation prior to the acquisition of FFB-CT by
First Fidelity Bancorporation. First Fidelity Bancorporation may be
deemed to be the indirect beneficial owner of the shares held by First
Fidelity by virtue of its ownership of all of the stock of First
Fidelity.
(3) Includes (i) 5,887 shares held for the account of Mr. Lacourciere under
the Employee Stock Ownership Plan of the Company (the "ESOP"), (ii)
1,000 shares issuable upon the exercise of Class A warrants, and 1,000
shares issuable upon the exercise of Class B warrants held by Mr.
Lacourciere, which warrants are currently exercisable and will expire
on December 8, 1997 and December 8, 1999, respectively, and (iii)
20,000 shares issuable upon the exercise of currently exercisable
options held by Mr. Lacourciere.
(4) Includes 180,325 shares issuable upon the exercise of currently
exercisable warrants.
(ii) Security Ownership of Management
The following table sets forth, as of September 30, 1996, the number of
shares of the outstanding voting securities of the Company beneficially
owned by each of the Company's directors and nominees for director,
each executive officer named in the Summary Compensation Table of the
proxy statement of the Company dated October 23, 1996, and all
directors and executive officers as a group, according to information
furnished by such persons to the Company.<F2>
<F2> This information is derived from the proxy statement of the Company as of
September 30, 1996.
<PAGE>
SECURITY OWNERSHIP OF MANAGEMENT
Title of Shares Percent
Name and Address Class Beneficially Owned of Class
Thomas M. Haythe Common 116,540 (1) 1.6%
Director of the Company
William J. Lacourciere Common 370,990 (2) 5.2%
Chairman of the Board,
President and Chief
Executive Officer of the
Company and Director of
the Company
Michael J. Needham Common 27,588 (3) *
Director of the Company
Photios T. Paulson Common 15,500 (4) *
Director of the Company
Steven J. Shulman Common 6,000 *
Director of the Company
Joseph A. Vincent Common 64,449 (5) *
Vice President Finance,
Chief Financial Officer,
Treasurer and Secretary
of the Company and
Director of the Company
All directors and executive Common 667,802 (1) (2) 9.1%
officers as a group (3) (4)
(seven persons) (5) (6)
* Less than one percent. The prior proxy statement and soliciting
material sent to shareholders indicated that Messrs. Needham and Shulman did
not own shares. At the time of such statements, the 13D Group was not aware of
any direct ownership of such shares by these Directors. As stated in the
soliciting material, this was based on lists of shareholders provided by the
Company to the 13D Group in response to the request of the 13D Group for
lists of the Company's shareholders.
(1) Includes (i) 14,844 shares issuable upon the exercise of currently
exercisable warrants held by Mr. Haythe, which warrant will expire on
December 31, 1997, and (ii) 10,744 shares issuable upon the exercise of
currently exercisable warrants held by Mr. Haythe, which warrants will
expire on March 10, 1999.
(2) Includes (i) 304,078 shares issuable upon the exercise of currently
exercisable warrants held by Mr. Lacourciere, which warrants will
expire on December 28, 1999, (ii) 5,887 shares held for the account of
Mr. Lacourciere under the ESOP, (iii) 1,000 shares issuable upon the
exercise of Class A warrants and 1,000 shares issuable upon the
exercise of Class B warrants held by Mr. Lacourciere, which warrants
are currently exercisable and will expire on December 8, 1997 and
December 8, 1999, respectively, and (iv) 20,000 shares issuable upon
the exercise of currently exercisable stock options held by Mr.
Lacourciere.
(3) Includes (i) 14,844 shares issuable upon the exercise of currently
exercisable warrants held by Mr. Needham, which warrants will expire on
December 31, 1997, (ii) 10,744 shares issuable upon the exercise of
currently exercisable warrants held by Mr. Needham, which warrants will
expire on March 10, 1999, and (iii) 1,000 shares owned by Simex, Inc.
(4) Includes 10,000 shares issuable upon the exercise of currently
exercisable warrants held by Mr. Paulson, which warrants will expire
on November 30, 2002.
(5) Includes (i) 3,158 shares held for the account of Mr. Vincent under the
ESOP, (ii) 200 shares issuable upon the exercise of Class A warrants
and 200 shares issuable upon the exercise of Class B warrants held by
Mr. Vincent, which warrants are currently exercisable and will expire
on December 8, 1997 and December 8, 1999, respectively, and (iii)
13,333 shares issuable upon the exercise of currently exercisable stock
options held by Mr. Vincent.
(6) Includes (i) 1,475 shares held for the account of Leslie E. Mace, Vice
President Engineering of the Company, under the ESOP, (ii) 24,535
shares issuable upon the exercise of currently exercisable warrants
held by Mr. Mace, which warrants will expire on March 22, 2000, (iii)
8,667 shares issuable upon the exercise of currently exercisable stock
options held by Mr. Mace, (iv) 25,452 shares held for the account of
Philip F. Nuzzo, Vice President - Medical Product Development and
Marketing, under the ESOP, and (v) 28,833 shares issuable upon the
exercise of currently exercisable stock options held by Mr. Nuzzo.
(e) To the best of the knowledge of the 13D Shareholders Group, there have
been no changes in control of Novametrix since the beginning of the last
fiscal year.
<PAGE>
Nominees for Election of Directors
DR. VARTAN GHUGASIAN
Dr. Ghugasian is 51 years old. Dr. Ghugasian has been a practicing
dentist in Massachusetts since 1972. Dr. Ghugasian has enjoyed a number
of academic appointments. These include a position as an Associate in
Prosthetic Dentistry, Harvard School of Dental Medicine, which he held
from 1980 until 1993. Dr. Ghugasian is a director of the Karagheusian
Commemorative Corporation of New York City. Dr. Ghugasian is a member of
the 13D Shareholders Group and owns 13,500 shares of the common stock of
the Corporation as well as 44,000 shares with Takuhe Ghugasian. Dr.
Ghugasian has had no business relationship with Novametrix and has no
family or business relationship with any existing directors or management.
PAUL A. COTE, ESQ.
Paul Cote is 66 years old. Mr. Cote has been a practicing lawyer in Maine
since 1955 and is the President and Director of his law firm, Cote, Cote &
Hamann. Mr. Cote is a member of the bar of several courts in the United
States, including the U.S. Supreme Court. Mr. Cote is a former judge.
Mr. Cote is a graduate of Boston University Law School. Mr. Cote was a
member of the Board of Directors of Secor Federal Savings & Loan,
Birmingham, Alabama, in 1992 and 1993, a bank with assets of $2 billion
and which was listed on NASDAQ. Mr. Cote was also a member of the
following Boards: Advisory Boards of Fleet Bank (1990-1992); Northeast
Bankshares Association (later became Norstar and then Fleet) (1975-1989);
and Auburn-Lewiston United Way (later to become Auburn-Lewiston United
Fund) (1957-1967). Mr. Cote, individually and with his wife Joan, owns
70,120 shares of the Corporation and 20,575 warrants, which accounts for
approximately 1.3% of the Corporation. Mr. Cote has had no business
relationship with Novametrix and has no family or business relationship
with any existing directors or management.
Plans of Dr. Ghugasian and Mr. Cote If Elected
If Dr. Ghugasian and Mr. Cote are elected they would work to maximize
shareholder values. They would propose, among other things, the
engagement of an investment banker to determine a true value for the
Company and to recommend a course of action to maximize those values.
They would propose that the Company adopt a plan to maximize those values.
They also oppose the merger with Andros. They believe the unanimous vote
by the current Board of Directors of the Company demonstrates a need for
new Directors. They believe that the merger is inappropriate for a number
of reasons, including those described in the following section. They
believe that basic business logic should have caused the directors to
reject the proposal. It is their opinion that issuance of about 4.4
million shares of the Company to Andros with a market value of
approximately $25 million (as of July 31, 1996) for a company, Andros,
that had a negative net worth (liabilities greater than assets) of $3.6
million (as of July 31, 1996), and the assumption by the Company's
subsidiary of Andros liabilities of $59 million (as of July 31, 1996), is
not a sound business deal.
Dr. Ghugasian and Mr. Cote believe that the broker management retained,
Tucker Anthony, Inc., is not suitable because of its rendering an opinion
upon which management relies, that the exchange ratio for the Andros
merger is fair to the Company and the shareholders, even though Tucker
Anthony has an interest in the shareholders voting in favor of the merger,
since Tucker Anthony's fee increases if the merger goes through.
If the shareholders do not vote to approve the Andros merger at the annual
meeting they will propose the Company take those steps necessary to
relieve the Company of any commitments or obligations arising from the
current Board of Directors' agreement to merge with Andros. Since Dr.
Ghugasian and Mr. Cote would be only two members of a six-member Board of
Directors, there can be no assurance that these plans will be adopted by
the full Board of Directors.
Compensation Of Directors And Executive Officers
Novametrix has not provided any compensation to any nominees of the
Schedule 13D Shareholders Group.
Other Matters To Be Acted Upon
VOTING PROCEDURES
The presence, in person or by proxy, of the holders of a majority of the
voting power of all the outstanding shares of common stock and Series B
preferred stock entitled to vote at the annual meeting is necessary to
constitute a quorum at the meeting or any adjournments thereof. Directors
of the Company are elected by a plurality vote. Adoption of the proposed
merger with Andros will require the affirmative vote of a majority of the
voting power of the shares present at the meeting, in person or by proxy,
and entitled to vote on that proposal. Abstentions and broker non-votes
(as defined below) will be counted as present for the purpose of
determining the presence of a quorum. For the purpose of determining the
vote required for approval of matters to be voted on at the meeting,
shares held by stockholders who abstain from voting will be treated as
being "present" and "entitled to vote" on the matter and, thus, an
abstention has the same legal effect as a vote against the matter.
However, in the case of a broker non-vote or where a stockholder withholds
authority from his proxy to vote the proxy as to a particular matter, such
shares will not be treated as "present" and "entitled to vote" on the
matter and, thus, a broker non-vote or the withholding of a proxy's
authority will have no effect on the outcome of the vote on the matter. A
"broker non-vote" refers to shares of common stock or Series B preferred
stock represented at the meeting in person or by proxy by a broker or
nominee where such broker or nominee (i) has not received voting
instructions on a particular matter from the beneficial owners or persons
entitled to vote and (ii) the broker or nominee does not have
discretionary voting power on such matter.
Original 13D Group Shareholders Proposal
It should be noted that, with respect to the original 13D Group
Shareholder Proposal to retain an investment banker, there were meetings
with Company officials, correspondence and other communications. In the
opinion of the 13D Group, these communications were not responsive to the
issue.
<PAGE>
Other Matters To Be Acted Upon-The Proposed Merger of Andros with the Company
PROPOSAL
Management of the Company has entered into an agreement with Andros
Holdings, Inc. ("Andros") in which Novametrix Acquisition Corp., a wholly
owned subsidiary corporation of the Company, would be merged with and into
Andros, a subsidiary of Genstar Capital Partners II, L.P. ("Genstar").
The agreement is effective and the merger will be consummated only if
there is an affirmative vote of a majority of the shares of the Company as
of September 27, 1996 that are present at the meeting approving of the
merger. Under the merger agreement, at the Effective Time of the merger
(the date the merger is consummated if approved by the shareholders) the
Company will issue to the stockholders of Andros (Genstar is the principal
stockholder of Andros and has a 98% ownership interest of Andros) on the
following: (1) shares of the Company's common stock constituting 38% of
the Company plus an opportunity to receive an additional 5% if certain
revenue or income thresholds are exceeded; and (ii) anti-dilution rights
enabling the Andros shareholders to maintain, without additional payment,
the 38% ownership interest (or 43% ownership as the case may be) as the
Company's options and warrants are exercised. The merger agreement also
provides that the Board of Directors of the Company shall be comprised of
(i) the members of the Company's Board of Directors immediately prior to
the Effective Time; and (ii) an equal number of directors appointed by
Andros. The agreement also provides that Genstar's Richard D. Paterson
shall become Chairman of the Board of the Company.
The 13D Group's Opposition to the Merger Proposal
The 13D Group opposes the merger proposal because it strongly believes
that the merger is not in the best interests of shareholders of the
Company. The reason for this position are as follows:
1. Dilution. Each shareholder's ownership interest in the Company will
be diluted by 38%, and 43% if the additional 5% is issued to Andros.
In other words, after the merger, he would only have 62% or 57% of his
former value. However, on a book value basis, without taking into
consideration post-merger adjustments by the company, the combination
of the company's net worth of $13,231,000 with the negative net worth
of Andros of $3,614,000 would reduce his per share book value as of
July 28, 1996 from $1.97 to $1.08 -- a decrease of 55% instead of only
38%.
2. Price. We believe the price paid for Andros is excessive:
(a) Andros will receive 4,389,586 shares of the Company with a market
value of approximately $25 million as of July 31, 1996 (based on a
share price of $5.75) plus an opportunity to receive an additional
approximately 575,000 shares, with a market value of about $3.3
million if certain sales or income thresholds are exceeded.
Andros will also receive anti-dilution rights regarding the more
than 2 1/2 million stock options and warrants of the Company.
That means that for each issue of shares of stock upon exercise of
warrants and options Andros will receive free additional shares of
stock. If all warrants and options are exercised this will mean
approximately 950,000 additional shares of the Company.
(b) the Company's subsidiary will assume $44 million of Andros' bank
debt and other liabilities, such as current liabilities and
deferred income taxes, of Andros of about $15 million (totalling
$59 million). Total assets of Andros are about $55 million, of
which $34 million are tangible assets and $21 million are
intangible assets. Substantially all of the assets are mortgaged
to lenders.
(c) Andros had a negative net worth of about $3.6 million on July 28,
1996.
(d) Andros had a net operating loss for the period ended July 31, 1996
of almost $20 million.
(e) Sales of Andros have not shown any significant improvement in the
last three years. For the year ended July 31, 1994 sales were
$57.7 million, declined to $42.8 million for the next year and
increased only to $43.2 million for the year ended July 31, 1996.
3. Assumption of Debt. We believe the deal represents an unwarranted
bail-out for Genstar - 98% owner of Andros. Genstar has an equity
investment of approximately $17 million in Andros and is receiving
Company stock of approximately $27 million and Andros is transferring
debt of approximately $59 million and assets of $55 million. Genstar
is bailed out because now it need rely not only on Andros' assets and
income stream to pay the Andros liabilities, but it also can use the
Company's income and assets. Since Andros had a negative net worth
and a loss, the addition of the Company's assets and future income
make it easier to pay off this debt and thereby provide for a return
on Genstar's investment.
4. Excessive Debt Structure. Management's press release dated August 2,
1996 announcing the merger refers to the combined sales if the Company
and Andros are merged. Management, however, failed to disclose in the
press release the additional debt that the Company will be assuming as
a result of the merger. Andros had bank debt prior to the merger of
approximately $44 million, all of which (together with $15 million of
other debt, such as current liabilities and deferred income taxes)
will be assumed by a subsidiary of the Company.
5. Sacrifice of Minimum Debt Currently of the Company. In contrast to
Andros, the Company prior to the merger was relatively debt free. As
of July 31, 1996, the Company had long term liabilities of about $2.4
million.
6. Voting Control. Current management of the Company has relinquished
independent control of the Company in exchange for a voting agreement
that gives the current directors the ability to elect 1/2 of the
Directors of the new merged Company and Genstar the ability to elect
the remaining 1/2 of the Board of Directors. Operation of any
corporation is controlled by its Board of Directors. In turn, the
Board of Directors are accountable to those persons who elect
them--the shareholders. Under the merger agreement and the voting
agreement, which accompanies the merger agreement and is a necessary
condition of consummating the merger, 1/2 of the directors of the
Board of Directors are to be nominated and elected by Andros. The
other 1/2 of the directors are the Board of Directors of the Company
immediately before the merger is completed. Even if the 13D Group
Board of Directors nominees, Dr. Vartan Ghugasian and Paul Cote, are
elected by shareholders to fill 2 seats on the Company's Board of
Directors the remaining 4 members of the Company's Board of Directors
are each management nominees. Thus, for a 12 person Board of
Directors, 10 directors would be Andros and Company management
nominees.
In addition, the voting agreement provides that Genstar is to vote all
its shares (which would be approximately 38% of the Company) in
election of directors for those persons nominated by a majority of the
current Board of Directors of the Company; i.e., current management.
Therefore, Genstar would be required to vote its shares for the
Company management nominees. Since Genstar itself will have almost
38% of the shares of the Company, the current directors of the Company
have virtually assured themselves of placing 1/2 of the directors of
the new merged company.
7. Possible Loss of Value. If the merger is approved, the shareholders
will retain a smaller ownership interest of a larger company. Nobody
can assure the shareholders that the value of their interests will be
higher (or lower) in the future as a result of the merger. Even the
opinion from Tucker Anthony, Inc. specifically disclaims any ability
to do so.
8. Sweetheart Registration Rights for Genstar. Under the agreement, the
Company agrees for a period of ten years on request to register all of
the Novametrix stock issued to Genstar and pay all of the registration
expenses including legal fees.
Long Term Incentive Plan - Management Proposal
We are strongly in favor of employee incentive programs which provide
incentives to employees, and not directors. We do not believe that the
Company's plan will accomplish this objective.
Of the 750,000 shares set aside for awards, up to 300,000 or 40% can go to
directors alone.
The Company has previously granted employees and directors options and
warrants for stock. The Company's 1996 Plan does not take these into
consideration or attempt to coordinate future Plan options with previous
grants.
In order to motivate other key employees, we feel that the plan should be
revised to take into consideration previous options given to directors.
13-D Group's Position Regarding Number Of Directors To Be Elected At The Annual
Meeting
The upcoming annual meeting of November 25, 1996 will permit the
shareholders to elect two Class A Directors. The Class B Directors were
elected at the 1994 annual meeting and will be elected at the 1997 annual
meeting and the Class C Directors were elected at the 1995 annual meeting
and will be elected at the 1998 annual meeting.
On August 15, 1994, prior to the issuance of the management's proxy
statement for the 1994 annual meeting at which Class B Directors were to
be elected, a Class B Director resigned. This created an imbalance in the
number of Directors: 3 Class A Directors; 1 Class B Director; and 2 Class
C Directors. Even though there was this imbalance and the shareholders
were voting for Class B Directors at the upcoming annual meeting in 1994,
the Board did not decrease the number of Class A Directors to 2 from 3 and
increase the number of Class B Directors from 1 to 2. The Board noted in
its 1994 proxy statement that there were three Class A Directors, who
would be elected at the 1996 Annual Meeting. Similar representations were
made in the 1995 proxy statement of the Board.
On April 25, 1996 the 13-D Group was formed and informed management that
it was seeking to have the shareholders adopt a proposal at the upcoming
meeting to increase shareholder values. At a telephone meeting on May 20,
1996 of the Board of Directors of the Company, Class A Director Steven
Shulman resigned and during the same meeting the Board reduced the number
of Class A Directors to 2 and increased the number of Class B Directors to
2. The Board then elected Mr. Shulman, who had just resigned as a Class A
Director, to be a Class B Director. As a Class B Director, Mr. Shulman
will not stand for election by the shareholders until the 1997 annual
meeting. As a Class A Director, however, he was scheduled to stand for
election at the upcoming annual meeting in 1996.
We believe the Board's action on May 20, 1996 violates the Certificate of
Incorporation and bylaws of the Company.
The Fifth Article of the Certificate of Incorporation provides that "the
directors of each class shall be elected to serve for a term of three
years. The By-laws may contain any provision regarding classification not
inconsistent with the terms hereof." In our opinion, Mr. Shulman's
continuation for four years on the Board contravenes this provision of the
Certificate of Incorporation.
Article IV, Section 1 of the By-laws provides that Directors shall be
elected at the annual meeting of the Stockholders, except as provided in
Section 2. Section 2 permits the Board to appoint a Director only if
there has been an increase in the number of Board members (which clearly
is not the case) or if there is a vacancy in the office of Director.
While the minutes of the May 20 meeting indicate that the Board appointed
Mr. Shulman to fill the vacancy in the Class B Directorship, in our
opinion this was not a true vacancy. Rather, it was created by the Board.
The minutes of the May 20 meeting indicate that this change in the number
of Class A and B Directors was done so that each Class would have
approximately 1/3 of the number of Directors as provided in the
Certificate of Incorporation. If that is the case, then why was such
reconfiguration not done by the Board prior to the 1994 annual meeting
when it was known, as specified in the 1994 proxy statement, that the
claimed disproportion of Class A and Class B Directors occurred.
Certainly, if such a move was necessary it should have been done prior to
the very meeting when the Shareholders elected the Class B Directors. Why
wait two years to make this change? Was the Board in violation of the
Certificate of Incorporation for two years?
EXHIBIT A
<TABLE>
<S> <C> <C> <C>
(iv)
(i) (ii) (iii) Principal
Name Business Address SS# Occupation
Paul A. Cote Cote, Cote & Hamann ###-##-#### Lawyer
54 Pine Street
P.O. Box 7206
Lewiston, ME 04243-7206
Joan P. Cote None ###-##-#### Homemaker
Takuhe Ghugasian None ###-##-#### Homemaker
Vartan Ghugasian, Vartan Ghugasian, D.M.D. ###-##-#### Dentist
D.M.D. The Colonial Building
100 Boylston Street
Suite 806
Boston, MA 02116
John Orestis North Country Associates ###-##-#### Health Care
Nursing Homes Provider
179 Lisbon Street
Lewiston, ME 04240
Thomas B. Dunham The Dunham Group ###-##-#### Real Estate
One Portland Square Broker
Portland, ME 04101
Sandra Dunham None ###-##-#### Homemaker
Armen Ghugasian 25 Fairfield Street ###-##-#### Photographer
Watertown, MA 02172
Richard Boulet None ###-##-#### Retired
John F. Gross Winthrop Veterinary ###-##-#### Veterinarian
Hospital, P.A.
RFD #2, Box 5720,
Rt. 202
Winthrop, ME 04364
Susan T. Gross Winthrop High School ###-##-#### Educator
Winthrop, ME 04364
Dana Gross None ###-##-#### Student
Andrew Gross None ###-##-#### Student
Lillian I. Allen Cormier Textiles ###-##-#### Customer
River Street Service
Sanford, ME 04073 Computer Input
John C. Allen Salem Five Mortgage ###-##-#### Loan
Corp. Originator
P.O. Box 840
Salem, MA 01970
Roland R. Batson 10 Swan Road ###-##-#### Developer
Standish, ME 04084
Adrienne R. Emmi None ###-##-#### Retired
Anthony N. Emmi None ###-##-#### Retired
Donn Gifford Wadleigh's, Inc. ###-##-#### Business/Owner
21 Water Street Operator
Hallowell, ME 04347
Linda Gifford Central Maine Title ###-##-#### Lawyer
Company
Linda Gifford Law Office
78 Winthrop Street
Augusta, ME 04330-5506
Robert R. Gladu P.O. Box 1037 ###-##-#### Investor
Lewiston, ME 04243
Ginette Gladu None ###-##-#### Homemaker
Edgar Morin RR 1, Box 2915 ###-##-#### Lunch Truck
Sanford, ME 04073 Operator
Raymond E. Lafayette Social Club ###-##-#### Manager/
Robichaud 28 Winter Street Bartender
Sanford, ME 04073
Normand F. Doyon P.O. Box 1777 ###-##-#### Self-
Lewiston, ME 04241 employed
Pauline G. Doyon None ###-##-#### Homemaker
Richard James 77 Charleston Square ###-##-#### Chiropractor
St. Charles, MO 63304 Self-employed
Diane James 1049 East Terra Lane ###-##-#### Travel Agent
Ofallon, MO 63366
William H. 40 Westminster Street ###-##-#### Business
Lagerson Lewiston, ME 04240 Owner
Pierre Levesque None ###-##-#### Self-employed
<PAGE>
<S> <C> <C> <C>
(vii)
Number of
(vi) Shares Owned
Has the participant Beneficial
(v) ever been convicted of (of which
(i) Name of Employer, Principal a criminal offense ___ consist
Name Business, Address in last 10 years of warrants)
Paul A. Cote Cote, Cote & Hamann No 90,695
Law firm (20,575)
54 Pine Street (w/Joan
P.O. Box 7206 P. Cote)
Lewiston, ME 04243-7206
Joan P. Cote None No See Paul A.
Cote
Takuhe Ghugasian None No 44,000
(4,000)
w/Vartan
Ghugasian
Vartan Ghugasian, Vartan Ghugasian, D.M.D. No 13,500 and
Dentist Office see Takuhe
The Colonial Building Ghugasian
100 Boylston Street
Suite 806
Boston, MA 02116
John Orestis North Country Associates No 143,960
Nursing Homes (69,460)
179 Lisbon Street
Lewiston, ME 04240
Thomas B. Dunham The Dunham Group No 5,370 (280)
One Portland Square
Portland, ME 04101
Sandra Dunham None No 74,100
(20,080)
Armen Ghugasian Self-employed No 6,000
25 Fairfield Street (1,000)
Watertown, MA 02172
Richard Boulet None No 128,750 (0)
<PAGE>
John F. Gross Winthrop Veterinary No 79,790 (1,900)
Hospital, P.A. and 23,445
RFD #2, Box 5720, (2,500)
Rt. 202 (w/Susan
Winthrop, ME 04364 Gross)
Susan T. Gross Winthrop High School No 15,315 (0)
School and (see John
Winthrop, ME 04364 Gross)
Dana Gross None No 2,950 (0)
Andrew Gross None No 3,680 (0)
Lillian I. Allen Cormier Textiles No 5,230
River Street (850)
Sanford, ME 04073
John C. Allen Salem Five Mortgage Corp. No 7,100 (830)
Bank
P.O. Box 840
Salem, MA 01970
Roland R. Batson Self-employed No 59,000
10 Swan Road (24,000)
Standish, ME 04084
Adrienne R. Emmi None No 21,000 (0)
(w/Anthony
Emmi)
Anthony N. Emmi None No See Adrienne
Emmi
Donn Gifford Wadleigh's, Inc. No 21,000 (5,000)
Petroleum Products (w/ Linda
21 Water Street Gifford)
Hallowell, ME 04347
Linda Gifford Central Maine Title No See Donn
Company Gifford
Linda Gifford Law Office
Law Firm
78 Winthrop Street
Augusta, ME 04330-5506
Robert R. Gladu Investment No 20,000 (0)
P.O. Box 1037 (w/Ginette
Lewiston, ME 04243 Gladu)
Ginette Gladu None No See Robert
Gladu
Edgar Morin Self-employed No 1,300 (400)
RR 1, Box 2915
Sanford, ME 04073
Raymond E. Lafayette Social Club No 10,900
Robichaud 28 Winter Street (8,000)
Sanford, ME 04073
Normand F. Doyon Self-employed No 11,500 (0)
P.O. Box 1777 (w/Pauline
Lewiston, ME 04241 Doyon
Pauline G. Doyon None No See Normand
F. Doyon
Richard James Self-employed No 56,300
77 Charleston Square (25,850)
St. Charles, MO 63304
Diane James Getaway Tours & Travel No 5,500 (4,000)
Travel Agency
1049 East Terra Lane
Ofallon, MO 63366
William H. Paragon Glass No 80,000
Lagerson 40 Westminster Street
Lewiston, ME 04240
Pierre Levesque Self-employed No 24,125
10 Eastern Avenue (2,200)
Center Conway, NH 03815
<PAGE>
<C> <C>
(viii)
Common Stock, Warrants or (ix)
<S> Units (2 Shares of Common Any Shares Per (viii)
Stock, 1 Class A Warrant, purchased through
(i) Sold (S) or Purchased (P) loans, amount of loan,
Name During the Last 2 years creditor and date
Paul A. Cote 2275 (units)-7/8/94(P) 29,585 (Warrants) (17,085
5000 (common) - 7/8/94 (S) Class A and 12,500 Class
785 (units) - 7/11/94 (P) B)-$51,000-Peoples
1735 (common) - 7/11/94 (S) Heritage Bank-1/5/95
1110 (units) - 8/19/94 (P)
1980 (common) - 8/25/94 (S) 13,150 (Warrants) (5,950
340 (common) - 8/29/94 (S) Class A and 7,200 Class
2275 (common) - 8/31/94 (S) B)-$30,0009.06-Peoples
560 (common) - 9/2/94 (S) Heritage Bank-5/3/95
1035 (units) - 9/2/94 (P)
215 (units) - 9/16/94 (P)
4000 (Class B Warrants)-12/9/94 (P)
3500 (Class B Warrants)-12/9/94 (P)
5460 (Class A Warrants)-12/12/94 (P)
11625 (Class A Warrants)-12/15/94 (P)
5000 (Class B Warrants)-12/15/94 (P)
15000 (Class A Warrants)-12/19/94 (P)
380 (common) - 4/12/95 (P)
380 (common) - 4/12/95 (P)
3750 (Class A Warrants)-5/5/95 (P)
1000 (Class B Warrants)-5/9/95 (P)
2200 (Class A Warrants)-5/11/95 (P)
5000 (Class B Warrants)-5/11/95 (P)
1200 (Class B Warrants)-6/20/95 (P)
5000 (Class A Warrants)-12/7/95 (S)
5000 (Class A Warrants)-12/7/95 (S)
7500 (Class A Warrants)-12/7/95 (S)
5000 (common)-12/12/95 (P)
4200 (common)-1/2/96 (S)
3000 (common)-1/3/96 (S)
15000 (common)-1/3/96 (S)
1000 (Class B Warrants)-1/8/96 (P)
2500 (Class B Warrants)-1/16/96 (P)
8000 (common)-1/18/96 (P)
7500 (common)-1/18/96 (P)
2500 (common)-1/18/96 (P)
1040 (Class B Warrants)-1/25/96 (P)
465 (Class B Warrants)-1/25/96 (P)
2000 (common)-5/28/96 (S)
2450 (common)-4/11/96 (S)
4100 (Class B Warrants)-6/12/96 (P)
4100 (Class B Warrants)-6/12/96 (S)
735 (Class B Warrants)-6/28/96 (S)
4465 (Class B Warrants)-6/28/96 (S)
2000 (Class B Warrants)-7/2/96 (S)
4500 (Class B Warrants)-7/15/96 (S)
5000 (Class A Warrants)-8/1/96 (S)
4000 (Class A Warrants)-8/5/96 (S)
4130 (common)-8/13/96 (P)
5300 (Class B Warrants)-8/22/96 (S)
12935 (Class A Warrants)-8/22/96 (S)
3605 (common)-9/3/96 (S)
Joan P. Cote See Paul A. Cote
<PAGE>
Takuhe
Ghugasian 1000 (common)-11/15/94 (P) None
2000 (common)-12/5/94 (P)
1000 (Class A Warrants)-12/5/94 (P)
1000 (Class B Warrants)-12/5/94 (P)
2000 (common)-12/27/94 (P)
2000 (Class A Warrants)-1/4/95 (P)
Vartan
Ghugasian, See Takuhe Ghugasian
John Orestis 2500 (common)-2/1/96 (P) None
12000 (common)-2/9/96 (P)
Thomas B.
Dunham
Sandra
Dunham 150 (units)-9/6/94 (P) 1000 (units)-$6,380-Livada
1000 (units)-9/8/94 (P) Margin Account-9/8/94
500 (common)-3/1/95 (P) 2500 (units)-$12,645-Fidelity
2000 (units)-3/20/95 (P) Margin Account-4/4/95
2500 (units)-3/28/95 (P) 5000 (units)-$25,557-Fidelity
5000 (units)-5/24/95 (P) Margin Account-6/1/95
2500 (units)-8/31/95 (P) 2500 (units)-$13,582-Fidelity
1500 (Warrants)-2/26/96 (P) Margin Account-8/31/95
3000 (common)-2/26/96 (P) 1500 (Warrants-$4,687-Fleet
3000 (Class B Warrants)-2/2/96 Bank-2/26/96
(P) 3000 (common)-$21,900-Fleet
3000 (Class A Warrants)-3/5/96 Bank-2/26/96
(P)
Armen
Ghugasian None
Richard 10000 (common)-8/29/94 (P) 18,000 (common)-$98,354-
Boulet 8000 (common)-11/15/94 (P) Peoples Heritage Bank-
3000 (common)-11/15/94 (P) 11/23/94
7000 (common)-11/18/94 (P) 20,000 (common)-$147,911.49-
800 (common) - 2/17/95 (P) Peoples Gerutage Bank-
500 (common) - 2/21/95 (P) 2/26/96
10000 (common) - 12/18/95 (S)
9000 (common) - 12/19/95 (S)
7600 (common) - 1/8/96 (S)
7000 (common) - 1/19/96 (P)
4500 (common) - 2/23/96 (P)
8500 (common) - 2/23/96 (P)
7000 (common) - 2/23/96 (P)
<PAGE>
John F.
Gross 4000 (common) - 8/12/94 (P) None
445 (common) - 8/19/94 (P)
6600 (common) - 9/7/94 (P)
3035 (units) - 9/7/94 (S)
140 (units) - 9/12/94 (S)
6500 (common) - 9/15/94 (P)
205 (units) - 9/21/94 (S)
9000 (common) - 10/7/94 (P)
4477 (units) - 10/17/94 (S)
600 (common) - 10/17/94 (S)
210 (common) - 10/19/94 (P)
2145 (common) - 11/10/94 (P)
2000 (common) - 11/22/94 (P)
1900 (Class B warrants) -
12/13/95 (P)
790 (common) - 2/8/96 (P)
Susan T.
Gross 6700 (common) - 9/7/94 (P) None
3000 (units) - 9/8/94 (S)
205 (units) - 9/9/94 (S)
215 (units) - 9/21/94 (S)
255 (common) - 10/19/94 (P)
John & Susan 2500 (Class A warrants)-2/15/95 (P) None
Gross 2000 (common)-2/24/95 (P)
(Jointly) 2870 (common)-2/24/95 (P)
Dana Gross 115 (common) - 7/12/94 (P) None
835 (common) - 9/14/94 (P)
Andrew Gross 800 (common) - 9/13/94 (P)
880 (common) - 9/14/94 (P)
Lillian I.
Allen 295 (units) - 6/9/94 (P) None
130 (units) - 8/3/94 (P)
610 (common) - 9/15/94(P)
200 (common) - 3/21/95(P)
320 (common) - 4/2/96 (P)
John C.
Allen 295 (units) - 6/9/94 (P) None
120 (units) - 8/4/94 (P)
335 (common) - 9/15/94 (P)
200 (common) - 3/21/95 (P)
870 (Class B Warrants) - 5/16/95
230 (Class B Warrants) - 6/27/95
320 (common) - 4/2/96 (P)
1100 (Class B Warrants) -4/29/96 (S)
Roland R.
Batson 1540 (common) - 7/11/94 (P) None
770 (warrants) - 7/11/94 (P)
Adrienne R.
Emmi None None
Anthony N.
Emmi None None
Donn Gifford 3000 (common) - 7/25/94 (P) None
3000 (common) - 8/4/94 (P)
1000 (common) - 4/18/96 (P)
Linda Gifford See Donn Gifford None
Robert R.
Gladu None
Ginette
Gladu None
Edgar Morin 200 (units) - 6/9/94 (P) None
Raymond E.
Robichaud 2000 (common) - 9/9/94 (P) None
900 (common) - 11/15/94 (P)
Normand F.
Doyon None
Pauline G.
Doyon None
Richard
James 2300 (Warrants) - 9/12/94 (P) None
3250 (Warrants) - 11/8/94 (P)
1000 (Warrants) - 4/13/95 (P)
Diane James 1000 (Warrants) - 9/12/94 (P) None
1000 (Warrants) - 4/13/95 (P)
William H. 10,000 (common) - 2/96 (P) None
Lagerson
Pierre
Levesque 700 (Class B Warrants) - 9/23/94 (P) None
700 (Class A Warrants) - 9/23/94 (P)
700 (Common) - 9/23/94 (P)
700 (Common) - 9/23/94 (P)
400 (Common) - 4/17/95 (P)
1000 (Common) - 5/24/95 (P)
2000 (Common) - 10/12/95 (P)
1500 (Common) - 2/12/96 (P)
330 (Common) - 4/16/96 (P)
<PAGE>
<C> <C> <C> <C>
(x) (xi) (xii) (xiii)
Membership in Number of Business Arrangements for
13D Group to shares owned Transactions future employment
<S> obtain by Associates with or business
election of (Business Novametrix or transactions with
(i) directors and partners) of management Novametrix
Name oppose merger participant
Paul A. Cote Yes None None None
Joan P. Cote Yes None None None
Takuhe Ghugasian Yes None None None
Vartan Ghugasian Yes None None None
John Orestis Yes None None None
Thomas B. Dunham Yes None None None
Sandra Dunham Yes None None None
Armen Ghugasian Yes None None None
Richard Boulet Yes None None None
John F. Gross Yes None None None
Susan T. Gross Yes None None None
John & Susan
Gross (Jointly) Yes None None None
Dana Gross Yes None None None
Andrew Gross Yes None None None
Lillian I. Allen Yes None None None
John C. Allen Yes None None None
Roland R. Batson Yes None None None
Adrienne R. Emmi Yes None None None
Anthony N. Emmi Yes None None None
Donn Gifford Yes None None None
Linda Gifford Yes None None None
Robert R. Gladu Yes None None None
Ginette Gladu Yes None None None
Edgar Morin Yes None None None
Raymond E.
Robichaud Yes None None None
Normand F.
Doyon Yes None None None
Pauline G.
Doyon Yes None None None
Richard James Yes None None None
Diane James Yes None None None
William H. Yes None None None
Lagerson
Pierre
Levesque Yes None None None
</TABLE>
PROXY
SOLICITED ON BEHALF OF NOVAMETRIX 13D SHAREHOLDER GROUP
Directors
1. Election of two directors.
Nominees: Dr. Vartan Ghugasian and Paul Cote
[ ] For Both Nominees [ ] Withhold All Nominees
Or withhold Authority to vote for any of the following nominees:
[ ] Dr. Vartan Ghugasian [ ] Paul Cote
The Novametrix 13D Shareholders Group recommends a vote "AGAINST" the
following items:
2. Approval and adoption of the Management Proposal to Merge with Andros
[ ] For [ ] Against [ ] Abstain
3. Approval of the 1996 Long Term Incentive Plan
[ ] For [ ] Against [ ] Abstain
The Novametrix 13D Shareholders Group takes no positon with regard to the
following item:
4. Ratification of appointment of Ernst & Young LLP as independent auditors
for fiscal 1997.
[ ] For [ ] Against [ ] Abstain
5. In their discretion, the proxies or each of them is authorized to vote
upon such other business as may properly come before the meeting, or any
adjournments thereof.
6. Please date and sign exactly as name appears hereon. Each executor,
administrator, trustee, guardian, attorney-in-fact and other fiduciary
should sign and indicate his or her full title. Only one signature is
required in the case of stock ownership in the name of two or more
persons.
No. of Shares _______________
Shareholder Name and Address
___________________________________________ ______________________, 1996
Signature Date
PLEASE DATE AND SIGN THE CARD AND RETURN IT PROMPTLY IN THE ENCLOSED ENVELOPE
(see reverse side)
REVOCABLE PROXY
NOVAMETRIX MEDICAL SYSTEMS, INC.
THIS PROXY IS SOLICITED ON BEHALF OF NOVAMETRIX 13D SHAREHOLDER GROUP
The stockholder of Novametrix Medical Systems, Inc. (Novametrix) named
herein hereby appoints RICHARD BOULET and JOHN ORESTIS, or either of them with
full power of substitution as proxy to cast all votes which the said stockholder
is entitled to cast at the Annual Meeting of the Stockholders of the Company to
be held on November 25, 1996, New York, New York, and at any adjournments
thereof, upon the matters listed on the reverse side. The said stockholder
hereby revokes any proxy or proxies heretofore given.
When proxies are properly dated, executed and returned, the shares they
represent will be voted at the annual meeting in accordance with your
instructions as stockholders. If no specific instructions are given, the shares
will be voted FOR the election of the nominees for directors set forth herein
and AGAINST the Merger Proposal, AGAINST the Stock Incentive Plan, and FOR
appointment of Ernst & Young LLP. Any proxy given by any stockholder may be
revoked by the stockholder prior to its exercise by voting in person at the
annual meeting, by giving written notice to the Secretary of Novametrix prior to
the annual meeting or by giving a later dated proxy.
(continued on reverse side)
NOVAMETRIX 13D SHAREHOLDERS GROUP
November 5, 1996
Dear Fellow Shareholders:
Management has set November 25, 1996 as the date of the annual
shareholders meeting to vote on various proposals, including a merger with
Andros. It has sent you a two hundred page book (Management's Proxy
Statement) full of financial tables, legal documents, opinions, projections,
estimates, etc., in support of the proposals.
THE 13D GROUP OPPOSES THE MERGER. The full statement of our position and
the back-up material is in the following pages of this letter and the enclosed
proxy statement. We urge you strongly to read this letter and proxy statement
and form a judgment. WE ARE AGAINST THE MERGER BECAUSE:
1. YOUR STOCK INTEREST IN THE COMPANY WOULD BE SEVERELY DILUTED, IN OUR
OPINION.
2. NOVAMETRIX WOULD BE GETTING A COMPANY IN EXTREMELY POOR FINANCIAL
CONDITION, INCLUDING HAVING A NEGATIVE NET WORTH, A NET OPERATING LOSS
IN THE MOST RECENT YEAR AND SALES THAT HAVE DECLINED SINCE 1994.
3. ANDROS HAS A HUGE DEBT THAT NOVAMETRIX'S SUBSIDIARY WOULD HAVE TO
ASSUME.
4. WE BELIEVE THE PRICE NOVAMETRIX IS PAYING FOR ANDROS IS EXCESSIVE
COMPARED TO WHAT NOVAMETRIX IS GETTING.
5. THE ANDROS DEBT LOAD IS SO LARGE THAT NOVAMETRIX COULD HAVE SEVERE
FINANCIAL PROBLEMS TRYING TO SERVICE IT.
6. MANAGEMENT'S CLAIMS AS TO FUTURE PROFITABILITY ARE BASED LARGELY ON
THEIR ESTIMATES, PREDICTIONS AND PROJECTIONS AS TO FUTURE FINANCIAL
RESULTS.
7. THE MERGER WOULD GIVE GENSTAR, WHICH OWNS ANDROS, TOO MUCH CONTROL
OVER THE AFFAIRS OF NOVAMETRIX.
AGAIN, WE URGE YOU TO READ THIS LETTER AND GET THE FULL STORY. ALSO PLEASE
CALL US AT 1-800-344-1666 IF YOU HAVE ANY QUESTIONS.
<PAGE>
PROPOSAL NUMBER 1: THE MERGER AGREEMENT
WE BELIEVE THAT THE FACTS CLEARLY SHOW THE MERGER IS A BAD DEAL FOR
SHAREHOLDERS AND SHOULD BE VOTED DOWN. HERE'S WHY:
1. WHAT IS ACTUALLY HAPPENING HERE?
Although the transaction is cast in the form of a merger and stock
exchange, the net result is actually a purchase and sale arrangement.
Novametrix (the Company), through a subsidiary, will acquire all of the
assets of Andros and pay Genstar Capital Partners II, L.P. (Genstar),
which is the 98% owner of Andros, with 4,389,586 shares of Novametrix
stock and assumption by the subsidiary of $59 million of Andros'
liabilities.
2. WHAT IS GENSTAR?
Genstar Capital Partners II, L.P. (Genstar), in a separate private
placement memorandum, states that it is in the business of buying and
selling companies using leveraged buy-outs through raising large amounts
of debt in an acquired company. Its principals have made more than sixty
acquisitions and fifty divestitures.
3. THE CURRENT INTEREST OF NOVAMETRIX SHAREHOLDERS WILL BE SEVERELY DILUTED.
As of July 28, l996 on a book value basis, combiningNovametrix and Andros
would have resulted in a 55% reduction in book value to a Novametirix
shareholder. Please see the enclosed proxy statement for details.
4. WE BELIEVE THE PRICE TO BE PAID FOR ANDROS IS BASED ALMOST ENTIRELY ON
GUESSES, ESTIMATES AND PROJECTIONS OF ITS FUTURE VALUE.
As of July 31, l996, Andros had:
A negative net worth of $3.614 million
Total liabilities of approximately $59 million. Total Assets of $55
million, of which $34 million are tangible assets and $21 million are
intangible assets. Substantially all of the assets are mortgaged to
lenders.
An operating loss of almost $20 million
25% sales decline from 1994 to 1995 and relatively flatsales in 1996.
Novametrix is paying over $25,000,000 worth of stock for Andros and its
subsidiary is assuming all its debt. (Please see the enclosed proxy
statement for details.)
Novametrix is providing to Genstar anti-dilution rights regarding the
approximately 2-1/2 million options and warrants so that Andros could
receive in the future an additional 950,000 shares of the Company free.
<PAGE>
WHERE IS ANDROS' VALUE?
Management claims that, in spite of all this, the future growth and
prospects of the combined companies will make the deal worthwhile. But,
even Management admits that these claims are based largely on
projected future performance, potential cost savings, potential synergies.
Management is hoping that these future developments will take place.
Management itself admits in its proxy statement "that no assurance can be
provided as to any future financial results".
5. IN OUR OPINION, THE "FAIRNESS OPINION" OF TUCKER ANTHONY IN FAVOR OF THE
MERGER CANNOT BE RELIED UPON.
Management relies on Tucker Anthony, its hired investment advisor, to
approve the merger as being fair to the Company and the shareholders. We
believe their fairness opinion is unreliable.
THEY ARE NOT IMPARTIAL. While Tucker Anthony has already received
fees for acting as a financial adviser and for rendering the opinion,
as Tucker Anthony states in its October 18, 1996 letter, a substantial
portion of their fee depends on the merger being successful. Tucker
Anthony has been paid some monies to date.
THEIR OPINION OF FUTURE PERFORMANCE IS BASED LARGELY ON ESTIMATES AND
PROJECTIONS GIVEN TO THEM BY MANAGEMENT.
THEY HAVE ASSUMED THAT SUCH PROJECTIONS WILL BE REALIZED. In other
words, in support of their opinion they are assuming that things will
happen just the way Management says they will.
6. IN OUR OPINION, THE COMPANY MAY HAVE SERIOUS FINANCIAL PROBLEMS IN
SERVICING THE ANDROS BANK DEBT OF $44 MILLION.
In 1997, principal and interest payments on the Andros term loan and
subordinated loans totalling $44 million will be almost $7 million.
In 1998, payments on these loans will be almost $8 million.
In l996, Novametrix had net operating income of $2.13 million. Andros,
for the year ended July 31, 1996, had an operating loss of almost $20
million.
WHERE IS THE DEBT SERVICE COMING FROM?
The banks have a mortgage on substantially all of the Andros assets to
secure the loans. If Management's predictions of future earnings do not
come true, the bank could be in a position to foreclose on the loan.
7. THE AGREEMENT GIVES GENSTAR EFFECTIVE CONTROL OF THE COMPANY.
A 38% - 43% single block of stock in itself amounts to practical voting
control.
In addition, a Voting Agreement between the parties gives Genstar (until
January l, 1999) the power to elect half of the directors.
Genstar will acquire in effect a negative veto over the Company's affairs.
8. SHOULD GENSTAR HAVE THAT MUCH CONTROL OF NOVAMETRIX?
According to the private placement memorandum, Genstar is in the business
of buying and disposing of companies. We believe its principal objective
is short term profits.
Andros is an example of how it operates. Before the Genstar acquisition,
(on May 1, 1996) Andros had approximately $26 million of cash and no bank
debt. Genstar used all of Andros own cash to pay out its shareholders and
then loaded the company with over $44 million of bank debt. Six months
after the acquisition, it wants to sell Andros to Novametrix under the
merger agreement.
PROPOSAL NUMBER 2: LONG TERM INCENTIVE PLAN
We are strongly in favor of employee incentive programs, which provide
incentives to employees and not directors. We do not believe that the
Company's plan will accomplish this objective.
Of the 750,000 shares set aside for awards, up to 300,000 or 40% can go to
directors alone.
The Company has previously granted directors options and warrants for
stock. As of August, 1995 directors had received 437,675 options and
warrants.
In order to motivate other key employees, we feel that the plan should be
revised to take into consideration previous options given to directors.
PROPOSAL NUMBER 3: ELECTION OF DIRECTORS
We urge you to vote for the election of Paul Cote and Vartan Ghugasian -
as directors who will truly represent the interests of shareholders on the
Board.
IF YOU AGREE WITH OUR POSITION, WE URGE YOU:
1. DO NOT SIGN AND RETURN THE -- COMPANY PROXY CARD.
2. DATE, SIGN, AND RETURN THE ENCLOSED GREEN PROXY CARD IN THE ENCLOSED
ENVELOPE.
VOTE NO CONFIDENCE -- VOTE THE GREEN CARD
NOVAMETRIX 13D SHAREHOLDERS GROUP<F1>
consisting of
John C. Allen, Sr. Donn Gifford
Lillian I. Allen Linda Gifford
Roland R. Batson Ginette Gladu
Richard Boulet Robert R. Gladu
Joan P. Cote Andrew Gross
Paul A. Cote Dana Gross
Normand F. Doyon John F. Gross
Pauline G. Doyon Susan T. Gross
Sandra Dunham Diane James
Thomas B. Dunham Richard James
Adrienne R. Emmi William Lagerson
Anthony N. Emmi Pierre Levesque
Armen Ghugasian Edgar Morin
Takuhe Ghugasian John Orestis
Vartan Ghugasian Raymond E. Robichaud
<F1>Each of us is a shareholder of Novametrix Medical Systems, Inc. and is a
member of the Novametrix 13D Shareholders Group. Collectively, we own in the
aggregate, including currently exercisable warrants, approximately 10.8% of the
common stock of Novametrix. None of us are members of management of the
Company or have any business relationship with management.
